Percutaneous nephrostomy as a marker of clinical vulnerability in non-metastatic muscle-invasive bladder cancer: prognostic and infectious implications - Top-Institutions - MDSpire

Percutaneous nephrostomy as a marker of clinical vulnerability in non-metastatic muscle-invasive bladder cancer: prognostic and infectious implications

  • By

  • İlkay Çıtakkul

  • Yasemin Bakkal Temi

  • Ece Baydar

  • Elif Şahin

  • Umut Kefeli

  • Devrim Çabuk

  • Kazım Uygun

  • May 29, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Kocaeli University Hospital Oncology Center
    Kocaeli University Hospital Oncology Center

    Kocaeli, Turkey

    Key Differentiators

    • Oncology
    • Urology

  • #2

    Kocaeli City Hospital
    Kocaeli City Hospital

    Kocaeli, Turkey

    Key Differentiators

    • Oncology
    • Urology

  • #3

    Fox Chase Cancer Center
    Fox Chase Cancer Center

    Philadelphia, Pennsylvania

    Key Differentiators

    • Oncology
    • Urology

  • #4

    Mount Sinai Tisch Cancer Center
    Mount Sinai Tisch Cancer Center

    New York, New York

    Key Differentiators

    • Oncology
    • Urology

  • #5

    Integrated Cancer Center Ghent
    Integrated Cancer Center Ghent

    Ghent, Belgium

    Key Differentiators

    • Oncology
    • Urology

Original Source(s)

Percutaneous nephrostomy as a marker of clinical vulnerability in non-metastatic muscle-invasive bladder cancer: prognostic and infectious implications

  • by İlkay Çıtakkul, Yasemin Bakkal Temi, Ece Baydar, Elif Şahin, Umut Kefeli, Devrim Çabuk, Kazım Uygun

  • May 29, 2026

Related Content

Recurrent pleuropulmonary blastoma type III initially misclassified as embryonal rhabdomyosarcoma on limited biopsy: a case report with pathogenic DICER1 variant

Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report

Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma